Is CVS Health About to Break Up? Here's What We Know
CVS Health stock is lower Tuesday on reports the healthcare company is conducting a strategic review of its operations, which includes a potential breakup.


CVS Health (CVS) stock is lower in Tuesday's session on news the pharmacy chain's board of directors is conducting a strategic review of its business, according to media reports.
CVS has hired bankers to assist in exploring options, including the potential separation of its retail and insurance units into two publicly traded companies, people familiar with the matter told Reuters. The discussions are still in the early stages and no plans have been finalized.
A CVS spokesperson declined to comment on the report, but did tell Reuters the following:

Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
"CVS's management team and Board of Directors are continually exploring ways to create shareholder value," the spokesperson said. "We remain focused on driving performance and delivering high-quality healthcare products and services enabled by our unmatched scale and integrated model."
The report comes as CVS faces pressure from activist investor Glenview Capital. The hedge fund recently took a sizable stake in the healthcare stock and met with CVS executives to propose changes to improve its operations, according to The Wall Street Journal.
Is CVS Health stock a buy, sell or hold?
CVS Health's troubles haven't been solely on the fundamental side. Indeed, shares have underperformed on the price charts, too, down 18% on a total return basis (price change plus dividends) so far this year vs the S&P 500's 22% gain. Still, Wall Street remains bullish on the large-cap stock.
According to S&P Global Market Intelligence, the consensus analyst target price for CVS stock is $67.14, representing implied upside of more than 8% to current levels. Additionally, the consensus recommendation is Buy.
Financial services firm BofA Securities is one of those with a Buy rating on CVS stock, along with a $77 price target.
"CVS' reported decision to pursue a strategic review would not be particularly surprising given the company's recent execution issues," says BofA Securities analyst Allen Lutz, who adds that he has mixed feelings about a potential breakup.
While it could reasonable in a normal environment "to assume that the health plan Aetna could obtain a higher earnings multiple as a standalone business," the insurance provider's underperformance in 2024 "is the main driver of CVS' weak share price, and it is unclear how much investors would reward that business as a standalone entity, especially on current year or next year's earnings."
Lutz believes a stabilization in Aetna's earnings could "generate substantial shareholder value" and "significant upside potential."
Related Content
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
Joey Solitro is a freelance financial journalist at Kiplinger with more than a decade of experience. A longtime equity analyst, Joey has covered a range of industries for media outlets including The Motley Fool, Seeking Alpha, Market Realist, and TipRanks. Joey holds a bachelor's degree in business administration.
-
‘Are You Better Off Than You Were 71 Days Ago?’ Cory Booker Marathon Senate Speech Highlights Tax Debate
Tax Policy A speech protesting Trump’s policies, including tax plans, breaks U.S. Senate records.
By Kelley R. Taylor Published
-
Stock Market Today: Stocks Are Mixed Before Liberation Day
Markets are getting into the freewheeling rhythm of a second Trump administration.
By David Dittman Published
-
Stock Market Today: Stocks Are Mixed Before Liberation Day
Markets are getting into the freewheeling rhythm of a second Trump administration.
By David Dittman Published
-
How to Invest in Sports
If it's springtime, Forbes is out with its annual list of baseball franchise values. The billions involved might make you wonder how to invest in sports.
By David Dittman Published
-
Winning Strategies for Financial Advisers as Clients' Lives Evolve
How can the wealth management industry help make life transitions easier for the adviser and the client?
By David Conti, CPRC Published
-
How Advisers Can Establish Relationships With HNW Prospects
These strategies can help to build influence with high-net-worth individuals, who are often looking to an adviser for insight rather than solutions.
By Jeremy Green, CFP®, CTFA, CLU®, CEBS®, AEP®, EA, MSFS Published
-
When Your Car Is Fixed, But You've Still Got the Problem
This reader's experience with trying to get squealing brakes fixed under an extended warranty mirrors what others are experiencing these days.
By H. Dennis Beaver, Esq. Published
-
Stock Market Today: Dow Rises 854 Points From Its Intraday Low
If there's one thing markets hate, it's uncertainty. But uncertainty is all they're getting these days.
By David Dittman Published
-
Seven Questions to Ask When Evaluating Personal Loan Options
Taking out a personal loan too hastily could lock you into unfavorable terms with an untrustworthy lender. Ask these questions before signing anything.
By David Kimball Published
-
How Much Does Being Rich Matter in Retirement?
After a certain point, having more money in retirement won't make you any happier, new research shows. Instead, physical health, a sense of purpose, and a minimal amount of non-mortgage debt are more relevant.
By Christy Bieber Published